Laboratory Services Expected to Commence by July and Ramp Up to Process 1,000 Samples per Month
MILTON, GA. , May 01, 2018 (GLOBE NEWSWIRE) -- Attis Industries, Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), an integrated technology and innovations holding company, today announced that it has entered into an agreement with Macon County General Hospital, a rural community hospital located in Lafayette, Tennessee, to assist in the operation of a new and improved hospital laboratory.
Laboratory services are an integral part of patient care that impact approximately 70% of medical decisions and comprise more than 80% of a patient's medical record. Chronic disease can be largely preventable through the appropriate screenings and a close partnership with the patient’s healthcare team. Early detection and treatment can save money on healthcare costs and prevent further health problems,
Attis Healthcare, a division of Attis Industries, and its team of seasoned healthcare professionals will assist the hospital in expanding their existing state-of-the-art hospital laboratory. Laboratory processing equipment has arrived in the Macon County General Hospital and they anticipate they will begin processing samples in the next 45 to 60 days. A hospital laboratory of this size can typically process, on average, upwards of 1,000 samples per month, once it is fully functioning.
The partnership between Attis Healthcare and the hospital will result in a profitable, highly functioning hospital laboratory that will provide improved health care for the citizens of Macon County. “Partnering with our hospital lab helps create jobs locally, improve hospital and community economics, and promote population health. In today's healthcare market, it is important for community hospitals to find new, innovative ways to improve hospital economics through partnerships and outsourcing,” stated Scott Tongate, Chief Financial Officer of Macon County General Hospital.
“The partnership with Macon County General Hospital is one of several partnerships with rural hospitals as we continue to expand our healthcare division across the country,” stated Jeff Cosman, CEO of Attis Industries. “Our services and business model are about making healthcare costs efficient for healthcare systems, communities and employers across the country, while also delivering improved patient care to the hospital's community and helping Attis and its partner hospitals fulfill their mission of delivering solutions to underserved communities across the nation.”
Attis Industries, Inc.
Attis Industries, Inc. (NASDAQ: ATIS) is a holding company defined by our commitment to servicing our customers with unwavering respect, fairness and care. We are focused on finding and implementing solutions for the resource needs and challenges of our customers with a fundamental objective to seek rewarding solutions through technology and innovation. Our healthcare business centers on creating community-based synergies through collaborations and software solutions. Our innovation business strives to create value from recovered resources. For more information, visit: www.attisind.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, the Company’s completion of the sale of its solid waste business; the ability of the Company to continue to meet the listing requirements of NASDAQ; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s go-forward business, and the risks identified and discussed under the caption “Risk Factors” in the Attis Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2018 and the other documents Attis files with the SEC from time to time. There will be events in the future, however, that Attis is not able to predict accurately or control. Attis’s actual results may differ materially from the expectations that Attis describes in its forward-looking statements. Factors or events that could cause Attis’s actual results to materially differ may emerge from time to time, and it is not possible for Attis to accurately predict all of them. Any forward-looking statement made by Attis in this press release speaks only as of the date on which Attis makes it. Attis undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.